Drugs / SHR-1909
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05162469 | Feb 2022 → Mar 2024 | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1909 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05162469 ↗ |
| Route | Intravenous | “intravenous injection” NCT05162469 ↗ |